Transforming growth factor-β type II receptor in pulmonary arteries of patients with very severe COPD

European Respiratory Journal

Volumn 28, Issue 3, 2006, Pages 556-562

  Beghe, B ^a   Bazzan, E ^a   Baraldo, S ^a   Calabrese, F ^a   Rea, F ^a   Loy, M ^a   Maestrelli, P ^a   Zuin, R ^a   Fabbri, L M ^b   Saetta, Marina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cytokines; Emphysema; Lung transplantation; Pulmonary hypertension; Vascular remodelling

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ADULT; ARTICLE; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DONOR; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTIMA; LUNG ARTERY; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RECEPTOR INTRINSIC ACTIVITY; TUNICA MEDIA; UPREGULATION;

FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY ARTERY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TUNICA INTIMA;

EID: 33751288591     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00077105     Document Type: Article

References (36)

1. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001; 46: 798-825.
2. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 892-905.
3. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107: 1193-1198.
4. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304-1309.
5. Naeije R, Barbera JA. Pulmonary hypertension associated with COPD. Crit Care 2001; 5: 286-289.
6. Santos S, Peinado VI, Ramirez J, et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1250-1256.
7. Peinado VI, Barbera JA, Ramirez J, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998; 274: L908-L913.
8. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717.
9. Peinado VI, Barbera JA, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1605-1611.
10. Vignola AM, Chanez P, Chiappara G, et al. Transforming growth factor-β expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 591-599.
11. 1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1951-1957.
12. Takizawa H, Tanaka M, Takami K, et al. Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2001; 163: 1476-1483.
13. Celedon JC, Lange C, Raby BA, et al. The transforming growth factor-β1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004; 13: 1649-1656.
14. Wu L, Chau J, Young RP, et al. Transforming growth factor-β1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 2004; 59: 126-129.
15. Su Z, Wen F, Feng Y, Xiao M, Wu X. Transforming growth factor-β1 gene polymorphisms associated with chronic obstructive pulmonary disease in Chinese population. Acta Pharmacol Sin 2005; 26: 714-720.
16. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001; 88: E2-E11.
17. Richter A, Yeager ME, Zaiman A, Cool CD, Voelkel NF, Tuder RM. Impaired transforming growth factor-β signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 1340-1348.
18. Massague J, Blain SW, Lo RS. TGF β signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
19. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000; 342: 1350-1354.
20. American Society for Transplant Physicians, American Thoracic Society, European Respiratory Society, International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 1998; 158: 335-339.
21. Sheppard MN. Practical pulmonary pathology. London, Edward Arnold, 1995.
22. Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19: 632-638.
23. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
24. Bartram U, Speer CP. The role of transforming growth factor β in lung development and disease. Chest 2004; 125: 754-765.
25. Grainger DJ, Kemp PR, Metcalfe JC, et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1995; 1: 74-79.
26. McCaffrey TA, Consigli S, Du B, et al. Decreased type II/ type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-β1. J Clin Invest 1995; 96: 2667-2675.
27. McCaffrey TA, Du B, Fu C, et al. The expression of TGF-β receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 1999; 31: 1627-1642.
28. Munoz-Antonia T, Li X, Reiss M, Jackson R, Antonia S. A mutation in the transforming growth factor β type II receptor gene promoter associated with loss of gene expression. Cancer Res 1996; 56: 4831-4835.
29. Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA. Lung adenocarcinoma global profiling identifies type II transforming growth factor-β receptor as a repressor of invasiveness. Am J Respir Crit Care Med 2005; 172: 729-737.
30. Loscalzo J. Genetic clues to the cause of primary pulmonary hypertension. N Engl J Med 2001; 345: 367-371.
31. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194.
32. 3. Diabetes 2003; 52: 824-828.
33. Friedl R, Li J, Schumacher B, et al. Intimal hyperplasia and expression of transforming growth factor-β1 in saphenous veins and internal mammary arteries before coronary artery surgery. Ann Thorac Surg 2004; 78: 1312-1318.
34. Orens JB, Boehler A, de Perrot M, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003; 22: 1183-1200.
35. Dos Santos CC, Slutsky AS. Invited review: mechanisms of ventilator-induced lung injury: a perspective. J Appl Physiol 2000; 89: 1645-1655.
36. D'Angelo E, Pecchiari M, Baraggia P, Saetta M, Balestro E, Milic-Emili J. Low-volume ventilation causes peripheral airway injury and increased airway resistance in normal rabbits. J Appl Physiol 2002; 92: 949-956.